Global Antibacterial (Drug) Resistance Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Antibacterial (Drug) Resistance Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Antibacterial drug resistance is the process that bacteria use to tolerate and overcome the effects of antibiotic drugs. Resistance can arise through mutations or can be acquired from other bacteria through plasmids.
Antibacterial (Drug) Resistance report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Antibacterial (Drug) Resistance market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Complicated Urinary Tract Infection (CUTI) and Complicated Intra-Abdominal Infections (CIAI) are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Antibacterial (Drug) Resistance industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Antibacterial (Drug) Resistance key manufacturers include Melinta Therapeutics, Allergan, Merck, Abbott Laboratories, Pfizer, GSK, PENDOPHARM, Absynth Biologics and Achaogen, etc. Melinta Therapeutics, Allergan, Merck are top 3 players and held % sales share in total in 2022.
Antibacterial (Drug) Resistance can be divided into Telavancin (Vibativ), Ceftaroline Fosamil (Teflaro/ Zinforo), Fidaxomicin (Dificid / Dificlir) and Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio), etc. Telavancin (Vibativ) is the mainstream product in the market, accounting for % sales share globally in 2022.
Antibacterial (Drug) Resistance is widely used in various fields, such as Complicated Urinary Tract Infection (CUTI), Complicated Intra-Abdominal Infections (CIAI), Blood Stream Infections (BSI) and Clostridium Difficile Infections (CDI), etc. Complicated Urinary Tract Infection (CUTI) provides greatest supports to the Antibacterial (Drug) Resistance industry development. In 2022, global % sales of Antibacterial (Drug) Resistance went into Complicated Urinary Tract Infection (CUTI) filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Antibacterial (Drug) Resistance market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Indication and Regions Listed in the Report
Melinta Therapeutics
Allergan
Merck
Abbott Laboratories
Pfizer
GSK
PENDOPHARM
Absynth Biologics
Achaogen
Acino Holdings
Aventis Pharma
Austell Laboratories
Assembly Biosciences
Arpida
Demuris
Evolva Holding
ContraFect
Cerexa
InterMune
Isis Pharmaceuticals
Lyndra
Microbecide
Morphochem
Nabriva Therapeutics
NanoSafe Coatings
Novexel
Osel
VenatoRx Pharmaceuticals
AAIPharma Services
ANTABIO
Segment by Type
Telavancin (Vibativ)
Ceftaroline Fosamil (Teflaro/ Zinforo)
Fidaxomicin (Dificid / Dificlir)
Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
Dalbavancin (Dalvance/ Xydalba)
Tedizolid Phosphate (Sivextro)
Oritavancin (Orbactiv/ Nuvocid)
Ceftolozane-Tazobactam (Zerbaxa)
Ceftazidime-Avibactam (Avycaz/ Zavicefta)
PHASE III DRUGS
Segment by Indication
Complicated Urinary Tract Infection (CUTI)
Complicated Intra-Abdominal Infections (CIAI)
Blood Stream Infections (BSI)
Clostridium Difficile Infections (CDI)
Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
Community Acquired Bacterial Pneumonia (CABP)
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Antibacterial (Drug) Resistance market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Antibacterial (Drug) Resistance, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Antibacterial (Drug) Resistance industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Antibacterial (Drug) Resistance in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Indication, Volume and Revenue analysis of Each Indication in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Antibacterial (Drug) Resistance introduction, etc. Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Antibacterial (Drug) Resistance market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Antibacterial (Drug) Resistance report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Antibacterial (Drug) Resistance market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Complicated Urinary Tract Infection (CUTI) and Complicated Intra-Abdominal Infections (CIAI) are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Antibacterial (Drug) Resistance industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Antibacterial (Drug) Resistance key manufacturers include Melinta Therapeutics, Allergan, Merck, Abbott Laboratories, Pfizer, GSK, PENDOPHARM, Absynth Biologics and Achaogen, etc. Melinta Therapeutics, Allergan, Merck are top 3 players and held % sales share in total in 2022.
Antibacterial (Drug) Resistance can be divided into Telavancin (Vibativ), Ceftaroline Fosamil (Teflaro/ Zinforo), Fidaxomicin (Dificid / Dificlir) and Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio), etc. Telavancin (Vibativ) is the mainstream product in the market, accounting for % sales share globally in 2022.
Antibacterial (Drug) Resistance is widely used in various fields, such as Complicated Urinary Tract Infection (CUTI), Complicated Intra-Abdominal Infections (CIAI), Blood Stream Infections (BSI) and Clostridium Difficile Infections (CDI), etc. Complicated Urinary Tract Infection (CUTI) provides greatest supports to the Antibacterial (Drug) Resistance industry development. In 2022, global % sales of Antibacterial (Drug) Resistance went into Complicated Urinary Tract Infection (CUTI) filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Antibacterial (Drug) Resistance market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Indication and Regions Listed in the Report
By Company
Melinta Therapeutics
Allergan
Merck
Abbott Laboratories
Pfizer
GSK
PENDOPHARM
Absynth Biologics
Achaogen
Acino Holdings
Aventis Pharma
Austell Laboratories
Assembly Biosciences
Arpida
Demuris
Evolva Holding
ContraFect
Cerexa
InterMune
Isis Pharmaceuticals
Lyndra
Microbecide
Morphochem
Nabriva Therapeutics
NanoSafe Coatings
Novexel
Osel
VenatoRx Pharmaceuticals
AAIPharma Services
ANTABIO
Segment by Type
Telavancin (Vibativ)
Ceftaroline Fosamil (Teflaro/ Zinforo)
Fidaxomicin (Dificid / Dificlir)
Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
Dalbavancin (Dalvance/ Xydalba)
Tedizolid Phosphate (Sivextro)
Oritavancin (Orbactiv/ Nuvocid)
Ceftolozane-Tazobactam (Zerbaxa)
Ceftazidime-Avibactam (Avycaz/ Zavicefta)
PHASE III DRUGS
Segment by Indication
Complicated Urinary Tract Infection (CUTI)
Complicated Intra-Abdominal Infections (CIAI)
Blood Stream Infections (BSI)
Clostridium Difficile Infections (CDI)
Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
Community Acquired Bacterial Pneumonia (CABP)
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Antibacterial (Drug) Resistance market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Antibacterial (Drug) Resistance, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Antibacterial (Drug) Resistance industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Antibacterial (Drug) Resistance in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Indication, Volume and Revenue analysis of Each Indication in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Antibacterial (Drug) Resistance introduction, etc. Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Antibacterial (Drug) Resistance market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices